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ABSTRACT
Objective: In many type 2 diabetes mellitus (T2DM) patients, metformin is prescribed concomitantly with hypolipidemic agents, particularly statins. 
Meanwhile, variability in response to metformin is one of the most important problems in the efficacy of this combination. The present study aims 
to evaluate the effect of adding atorvastatin with metformin on the glycemic control, adiposity indices, and lipid profile of overweight patients newly 
diagnosed with type T2DM.
Methods: A total of 50 overweight patients with T2DM were allocated into two groups, the first one received 850 mg/day of sustained release 
metformin and the second group received 10 mg/day atorvastatin in addition to the metformin. The patients were followed for 90 days through 
evaluating fasting serum glucose (FSG), glycated hemoglobin (HbA1c), body mass index (BMI), visceral adiposity index (VAI), and the lipid profile at 
baseline and after 90 days. In addition, the safety of the protocol was monitored through the evaluation of the renal and liver functions.
Results: HbA1c, FSG, BMI, and VAI values were significantly decreased in both treatment groups compared with baseline. Meanwhile, the combination 
improves all the lipid profile components with respect to the baseline. No significant differences reported between the two groups regarding all the 
measured parameters. The addition of atorvastatin produced a slight but significant negative impact on the renal and liver functions.
Conclusion: Addition of 10 mg/day atorvastatin with metformin in the treatment of newly diagnosed T2DM overweight patients did not produce 
significant improvement in glycemic control, adiposity index, and lipid profile compared with the use of metformin alone.
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INTRODUCTION
Many studies have concluded that the prescribing practice during 
the treatment of type 2 diabetes mellitus (T2DM) focused on the 
use of a combination therapy to target most of the associated risk 
factors [1,2]. The therapeutic benefits of statins as hypolipidaemic 
agents are recognized not only in patients with dyslipidemia [3,4] but 
also in patients early diagnosed or already having glucose metabolism 
disorders [5,6]. This may lead to the suggestion that patients early 
diagnosed with T2DM may benefit the use of statins, like atorvastatin, 
as “add-on” treatment with metformin in the treatment of patients 
suffering from impaired glucose metabolism compared with the 
use of metformin alone. The pathophysiological processes of T2DM 
may negatively impact the plasma lipids and lipoproteins, and the 
patients with T2DM often complain of dyslipidemia that enhances the 
risk of cardiovascular diseases (CVDs) [7,8]. Many reports indicated 
that around 80% of T2DM patients die due to its cardiovascular 
complications (CVD) [9], and the adjunct use of statins may reduce the 
CVD risks in those patients [10] and recommend early administration 
of these lipid-lowering agents in diabetic patients to prevent CVD 
mortality [11]. In newly diagnosed T2DM cases, the American Diabetes 
Association recommends changing lifestyle and starting metformin 
therapy [12]. Metformin has pleiotropic effects and can improve lipid 
metabolism and vascular function; although the inconsistent response 
to metformin was problematic in the efficacy of this drug [13] and other 
drugs such as statins may be added to the treatment protocol. However, 
accumulating evidence indicates that concomitant use of statins may 
negatively impact glycemic control and worsen the symptoms of 
T2DM [14]. We, therefore, performed a pilot clinical study to evaluate 
the effect of adding a low dose of atorvastatin with the prescribed dose 
of metformin on the treatment outcome of overweight newly diagnosed 
patients with T2DM.
METHODS
Patients and study design
A total of 50 newly diagnosed patients with T2DM with age range 
of 47.8±7.4 years and prescribed a sustained release 850 mg/day of 
metformin, after inappropriate management with dietary restriction, 
were enrolled in this open-label multicenter pilot study. All patients 
were newly diagnosed according to the WHO criteria [15] and 
underwent a physical examination and information about their 
medical history, demographic parameters, and medication history 
were obtained by questionnaire. The exclusion criteria include patients 
with T1DM, previous history of renal failure, autoimmune and liver 
diseases, serious chronic disorders, and pregnancy. The patients were 
randomly allocated into two groups (25 patients each) and followed 
for 90 days in this pilot study. During this period, the first group 
received 850 mg/day metformin (Merck Santé SAS, Lyon, France), 
while the second group consumed 10 mg/day of atorvastatin (Pfizer 
Ltd, Kent, UK) with the same metformin dose of the first group. Of 50 
participants, 17 were female and 33 were male. The patients received 
a constant dose regimen of metformin during the 90-day study period. 
In addition, few of them were already prescribed other drugs such 
as aspirin, calcium channel blockers, angiotensin-converting enzyme 
inhibitors, and angiotensin receptor blockers (Table 1). The study 
protocol was approved by the local Ethics Committee at Al-Rafidain 
University College in accordance with the principles of the Helsinki 
Declaration. All the enrolled patients provided written informed 
consent to participate in this pilot study.
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Anthropometric measurements
Body weight, wrist circumference, waist circumference (WC), and body 
mass index (BMI) were obtained for each participant at baseline and 
the end of the 90-day treatment.
Measurement of the visceral adiposity index (VAI)
The VAI was a gender-specific mathematical model based on simple 
anthropometric (BMI and WC) and functional parameters (triglyceride 
[TG] and high-density lipoprotein cholesterol [HDL-C]) and considered 
as an indicator of body fat distribution and function. It was calculated 
utilizing the formula of Amato et al. [16]. The distribution pattern of 
adipose tissue was corrected for TG and HDL-C levels to determine the 
VAI as follows:
Female VAI = (WC/36.58+(1.89×BMI))×(TG/0.81)×(1.52/HDL-c)
Male VAI = (WC/39.68+(1.88×BMI))×(TG/1.03)×(1.31/HDL-c),
Where, WC is expressed in cm, BMI in kg/m2, TG in mmol/l, and HDL-c 
in mmol/l.
Biochemical measurements
Blood samples (10 ml) were obtained by venipuncture from 12 h 
fasted patients at baseline (zero time) and after the 90-day treatment. 
Approximately 2.0 ml of the blood was kept in EDTA containing tubes 
for the determination of glycated hemoglobin (HbA1c) by colorimetric 
methods (Roche-Cobas C 311; Roche Diagnostics GmbH, Mannheim, 
Germany). The remaining 8.0 ml was drawn into plain tubes and allowed 
to clot before centrifuging at ×300 g for 20 min to obtain the serum. 
The serum was either analyzed immediately or stored at −20°C for 
later use. The fasting serum glucose (FSG), TG, cholesterol, low-density 
lipoprotein cholesterol (LDL-C), HDL-C, creatinine levels, aspartate 
transaminase, and alanine aminotransferase activities were determined 
colorimetrically (Roche-Cobas C 311, Roche Diagnostics GmbH).
Statistical analysis
The data were statistically evaluated utilizing GraphPad Prism 5.1 
software (GraphPad Software Inc., La Jolla, CA, USA). Continuous 
variables were presented as mean ± standard deviation. 
Discrete variables were presented as numbers and frequencies. 
Discrete variables were analyzed using the Chi-square test, while 
paired t-test was used to evaluate the difference between baseline 
and day 90 values. Analysis of variance was used to determine the 
significant difference between means of independent samples, 
confirmed by Bonferroni’s post hoc analysis. p<0.05 was considered 
for statistical significance.
RESULTS
Table 1 shows no significant differences (p>0.05) between the baseline 
anthropometric characteristics and the biochemical markers of 
both treatment groups of the T2DM patients enrolled in the present 
study. In Table 2, treatment of the newly diagnosed T2DM patients 
with metformin alone produced significant reduction in the serum 
cholesterol level and the LDL/HDL ratio (p<0.05) compared with the 
corresponding baseline values, while the other components of lipid 
profile were not significantly changed (p>0.05). Moreover, the addition 
of 10 mg/day of atorvastatin to the treatment protocol in the second 
group significantly improves all the lipid profile markers after 90 days 
compared with baseline values. However, analysis of data using ANOVA 
and post hoc test did not show significant differences between the two 
treatment groups after 90 days (p>0.05). (Fig. 1)
In the present study, Fig. 2 indicates that treatment with metformin alone 
significantly decreases all the adiposity markers (Fig. 3 a-d) compared 
with the baseline values (p<0.05). Meanwhile, the combination of 
metformin with atorvastatin significantly improves these markers, 
except for the WC (Fig. 3a) compared with the baseline values. However, 
both treatment groups did not show significant differences between 
each other after 90 days of treatment (ANOVA, p>0.05). Regarding 
the impacts of adding atorvastatin to the metformin protocol, Fig. 3 
indicates that in both groups of T2DM patients the glycemic control 
markers (FSG and HbA1c) were significantly decreased after 90 days 
of treatment (p<0.05) compared with their corresponding baseline 
values (Fig. 3a and b). However, both treatment approaches did not 
significantly differ from each other (ANOVA, p>0.05) in this regard. 
In Table 3, the use of metformin alone did not negatively impact the 
markers of renal and hepatic functions after 90 days of treatment, 
compared with the baseline values; however, it significantly decreases 
serum glutamic-pyruvic transaminase (GPT) level compared with 
baseline. Meanwhile, the inclusion of atorvastatin produces a significant 
elevation of serum GPT and creatinine levels compared with baseline 
values (p<0.05); though the post-treatment values are still within the 
normal reference values.
DISCUSSION
In the present study, the use of metformin in newly diagnosed patients 
with T2DM improves body weight and glycemic control; however, the 
addition of low-dose atorvastatin to the treatment protocol did not 
improve these outcomes. Metformin, in a long-term study, reduces the 
risk of macrovascular disease after a follow-up period of 4.3 years [17], 
and this beneficial effect supports the clinical decision to continue 
metformin treatment in any patient with T2DM unless contraindicated. 
The result of the present study is consistent with that reported in an 
experimental animal model, which indicates that the combination of 
atorvastatin with metformin did not produce a better lipid-lowering 
effect than atorvastatin [18]. These clinical and experimental data are 
consistent with many previously published clinical and preclinical 
data [17,19]. In addition, Forouzandeh et al. reported that metformin 
markedly decreased atherosclerotic plaques without any effect on the 
cholesterol level in apoE-/- mice maintained on a high-fat diet [20]. 
These data may offer inconsistent idea regarding the addition of statins 
to metformin in newly diagnosed T2DM patients and may add more 
risks of adverse effects and cost burden.
The increased risk of impaired glucose metabolism due to the use of 
statins in T2DM patients was recognized in many reports; however, 
such therapeutic indication was not themselves major contributors to 
the increased risk of DM complications [10]. Moreover, the participants 
in such a type of studies who were prescribed statins already present 
with higher serum glucose levels at baseline, yet such observation 
cannot be used to explain the higher rates of DM among statin users [21]. 
In addition, our study indicated that 10 mg/day did not increase the 
HbA1c and serum glucose levels, but there was no additional significant 
improvement in the studied markers when compared with the metformin-
treated group. However, Cheng et al. [22] reported a significant decrease 
Table 1: Baseline characteristics of the T2DM patients
Parameters Met n=24 Met+Atorn=21 p
Age (year) 46.8±7.4 49.1±7.2 0.32
Male n, (%) 16 (66.7) 12 (57.1) 0.21
Weight (kg) 96.2±15.2 89.6±12.0 0.12
BMI (kg/m2) 33.6±6.2 32.8±4.1 0.62
WC (cm) 116.4±8.9 114.1±8.12 0.38
VAI 2.3±1.05 2.51±1.0 0.52
Biochemical markers
HbA1c (%) 8.1±1.7 7.6±0.9 0.14
FSG (mmol/l) 11.4±3.3 11.2±2.1 0.88
TG (mmol/l) 1.84±0.95 1.9±0.7 0.82
TC (mmol/l) 4.6±1.3 4.7±1.2 0.71
HDL-C (mmol/l) 1.3±0.4 1.2±0.3 0.9
LDL-C (mmol/l) 2.3±0.87 2.2±0.9 0.78
Values are mean±SD, n: The number of patients, 
Met: Metformin, Ator: 10 mg atorvastatin, BMI: Body mass 
index, WC: Waist circumference, VAI: Visceral adiposity index, 
HbA1c: Glycated hemoglobin, FSG: Fasting blood glucose, TG: Triglyceride, 
TC: Total cholesterol, HDL-C: High-density lipoprotein cholesterol, 
LDL-C: Low-density lipoprotein cholesterol, SD: Standard deviation
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in the clearance of serum glucose induced by treatment with atorvastatin 
at approximately 50 mg/rabbit/day for 16 weeks. Moreover, it was 
previously reported that statin-induced dysregulation of glycemic control 
is both dose- and time-dependent [23,24].
When we analyzed the effect of metformin alone on the lipid profile, 
our findings showed that only TG levels and LDL/HDL ratio were 
significantly improved; however, these effects were not significantly 
different compared with its combination with atorvastatin that 
improves all lipid profile components. These results indicated that the 
addition of atorvastatin with metformin did not influence the lipid-
lowering effects of monotherapy with metformin in newly diagnosed 
patients with T2DM. In previous studies, although metformin 
moderately improves the lipid profile, there were inconsistencies 
in its effects on the lipid parameters [7]. Moreover, many reports 
indicated that polymorphism in the OATP1B1 transporter gene 
may affect the area under the curve of oral antidiabetic agents [25]. 
Therefore, such uptake-transporter-mediated drug interactions may 
be involved in the differential effects of atorvastatin that may influence 
metformin response, which is not clearly revealed due to the short 
duration of the study. Importantly, other reports have shown that the 
atorvastatin-induced impairment of glycemic control was completely 
reversed by metformin [26]; this may explain the non-significant 
differences reported in the present study between the two groups of 
T2DM patients. Accordingly, the addition of atorvastatin to metformin 
therapy in newly diagnosed T2DM patients with a relatively normal 
lipid profile may be irrational and cost ineffective and the emergence 
of adverse effects may be highly expected with long-term use. 
Moreover, our results of the safety profile for metformin/atorvastatin 
combination treatment indicate that the addition of atorvastatin may 
negatively impact the function of the liver and/or kidneys, which is 
consistent with previous reports [27,28]. It has been reported that 
atorvastatin is more effective in reducing the atherogenic index 
in responders of metformin than in non-responders, which may 
indicate higher atherogenic characteristics in the non-responders. 
Accordingly, newly diagnosed patients with T2DM who show 
inadequate response to metformin may need better treatment 
approaches to lower atherogenic lipids. According to a program 
Fig. 1: Flowchart of the study; n: The number of patients; 
Met: Metformin; Ator: Atorvastatin
Fig. 2: Effects of metformin alone or its combination with atorvastatin on the markers of adiposity: (a) Waist circumference; (b) wrist 
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suggested in a review article [29], niacin or high-dose omega-3 
fatty acid supplementation could be used in newly diagnosed T2DM 
patients with borderline values of lipid profile, secondary to lifestyle 
modifications before using a potent statin such as atorvastatin as the 
first treatment priority.
CONCLUSION
According to our findings, the addition of 10 mg/day atorvastatin with 
metformin in the treatment of newly diagnosed T2DM patients did not 
produce significant improvement in glycemic control, adiposity index, 
and lipid profile compared with the use of metformin alone. The impact 
of the combination on the liver and kidney functions should be strongly 
considered.
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